Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technology.

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife (2014) 0.87

Exploiting holistic approaches to model specificity in protein phosphorylation. Front Genet (2014) 0.81

Function through bio-inspired, synthesis-informed design: step-economical syntheses of designed kinase inhibitors†Dedicated to Max Malacria, a friend and scholar whose science and creative contributions to step-economical synthesis have inspired us all and moved the field closer to the ideal.‡Electronic supplementary information (ESI) available: Synthetic procedures and spectral data. See DOI: 10.1039/c4qo00228hClick here for additional data file. Org Chem Front (2014) 0.77

Protein networks and activation of lymphocytes. Curr Opin Immunol (2015) 0.75

The protein kinase complement of the human genome. Science (2002) 35.36

The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73

A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature (2000) 10.16

Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun (1986) 7.96

TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol (2012) 7.01

Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol (2011) 3.72

TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell (1995) 3.56

Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18

EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med (2012) 2.65

Regulation of EphA 4 kinase activity is required for a subset of axon guidance decisions suggesting a key role for receptor clustering in Eph function. Neuron (2005) 1.44

Catalytic domain crystal structure of protein kinase C-theta (PKCtheta). J Biol Chem (2004) 1.38

On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine. Chem Biol Drug Des (2009) 1.30

Unraveling cell division mechanisms with small-molecule inhibitors. Nat Chem Biol (2006) 1.04

Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proc Natl Acad Sci U S A (2011) 1.01

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology. ACS Chem Biol (2013) 0.94

A chemical genetic approach reveals distinct EphB signaling mechanisms during brain development. Nat Neurosci (2012) 0.91

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63

IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01

Targets of the cyclin-dependent kinase Cdk1. Nature (2003) 8.05

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15

T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 5.97

The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61

Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53

Global analysis of Cdk1 substrate phosphorylation sites provides insights into evolution. Science (2009) 5.37

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43

The site-specific installation of methyl-lysine analogs into recombinant histones. Cell (2007) 4.22

Cyclin specificity in the phosphorylation of cyclin-dependent kinase substrates. Nature (2005) 4.08

Features of selective kinase inhibitors. Chem Biol (2005) 4.07

Rewiring of genetic networks in response to DNA damage. Science (2010) 4.03

The unfolded protein response signals through high-order assembly of Ire1. Nature (2008) 3.87

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79

Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74

The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. Nat Cell Biol (2005) 3.61

Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35

A chemical-genetic strategy implicates myosin-1c in adaptation by hair cells. Cell (2002) 3.34

Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32

Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol (2007) 3.32

Sequential E2s drive polyubiquitin chain assembly on APC targets. Cell (2007) 3.26

Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science (2010) 3.20

Functional organization of the S. cerevisiae phosphorylation network. Cell (2009) 3.15

The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14

Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99

A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 2.93

Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science (2009) 2.82

Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77

The F box protein Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover and cotranscriptional mRNA processing. Cell (2005) 2.75

Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol Biol Cell (2003) 2.72

Evolution of phosphoregulation: comparison of phosphorylation patterns across yeast species. PLoS Biol (2009) 2.67

Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med (2007) 2.65

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res (2007) 2.62

Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci U S A (2008) 2.53

A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat Methods (2005) 2.47

Analysis of activator-binding sites on the APC/C supports a cooperative substrate-binding mechanism. Mol Cell (2009) 2.45

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42

A semisynthetic epitope for kinase substrates. Nat Methods (2007) 2.40

Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A (2007) 2.37

Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci Signal (2010) 2.36

Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature (2012) 2.33

Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell (2008) 2.32

JNK2 is a positive regulator of the cJun transcription factor. Mol Cell (2006) 2.32

Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol (2007) 2.31

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28

An architectural map of the anaphase-promoting complex. Genes Dev (2006) 2.27

Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Mol Cell Biol (2004) 2.26

Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature (2010) 2.25

Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell (2007) 2.22

An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol (2008) 2.21

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20

Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev (2008) 2.14

An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 2.11

To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J Cell Biol (2006) 2.10

Chemical genetics: where genetics and pharmacology meet. Cell (2007) 2.09

Arabidopsis MAP kinase 4 regulates salicylic acid- and jasmonic acid/ethylene-dependent responses via EDS1 and PAD4. Plant J (2006) 2.07

Positive feedback sharpens the anaphase switch. Nature (2008) 2.07

A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature (2011) 2.07

Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J Cell Biol (2010) 2.07

Tuning the activation threshold of a kinase network by nested feedback loops. Science (2009) 2.03

A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med (2011) 1.97

A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci U S A (2007) 1.97

Cdk and APC activities limit the spindle-stabilizing function of Fin1 to anaphase. Nat Cell Biol (2006) 1.96

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J (2008) 1.96

Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc Natl Acad Sci U S A (2003) 1.93

Modulation of the mitotic regulatory network by APC-dependent destruction of the Cdh1 inhibitor Acm1. Mol Cell (2008) 1.93

The APC subunit Doc1 promotes recognition of the substrate destruction box. Curr Biol (2005) 1.90

The cyclin-dependent kinase (CDK) family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity. Cell Cycle (2006) 1.90

Hierarchical modularity and the evolution of genetic interactomes across species. Mol Cell (2012) 1.88

Cascades of multisite phosphorylation control Sic1 destruction at the onset of S phase. Nature (2011) 1.86

A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. Cell (2013) 1.84

The Doc1 subunit is a processivity factor for the anaphase-promoting complex. Nat Cell Biol (2002) 1.84

Phosphorylation of the transcription elongation factor Spt5 by yeast Bur1 kinase stimulates recruitment of the PAF complex. Mol Cell Biol (2009) 1.82

The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem (2011) 1.80

Cyclin-dependent kinases: a family portrait. Nat Cell Biol (2009) 1.80

Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol (2009) 1.78

Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem (2004) 1.77

Maintenance of hormone-sensitive phosphoinositide pools in the plasma membrane requires phosphatidylinositol 4-kinase IIIalpha. Mol Biol Cell (2007) 1.77

Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol (2012) 1.74

The effect of H3K79 dimethylation and H4K20 trimethylation on nucleosome and chromatin structure. Nat Struct Mol Biol (2008) 1.73

Cdk1-dependent phosphorylation of Cdc13 coordinates telomere elongation during cell-cycle progression. Cell (2009) 1.72